Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Heres what the clinical evidence shows: Study Scope: 900+ participants across 6 randomized, double-blind, placebo-controlled trials Safety Profile: Indistinguishable from placebo in tolerability assessments Serious Events: Zero serious adverse events attributed to AOD-9604 Withdrawals: No treatment-related discontinuations in any trial Common Effects: Mild headache and minor GI symptoms at rates similar to placebo IGF-1 Impact: No effect on insulin-like growth factor-1 levels Metabolic Safety: No negative impact on glucose metabolism or insulin sensitivity Immunogenicity: Zero participants developed anti-AOD9604 antibodies The following analysis provides complete details on the clinical trial evidence supporting AOD-9604s favorable safety profile
For a 5mg vial, add 2mL of bacteriostatic water
Pale skin, weakness, tiredness, and lightheadedness
Typical oral regimen: 250500 mcg 12 times daily, depending on severity of symptoms or goals
Food Chemistry
TB-500 is a synthetic version of thymosin beta-4 and is often examined alongside growth factors and actin-related processes
